<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002131</url>
  </required_header>
  <id_info>
    <org_study_id>234D</org_study_id>
    <secondary_id>22-93-254</secondary_id>
    <nct_id>NCT00002131</nct_id>
  </id_info>
  <brief_title>A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To examine the safety and efficacy of two doses of vesnarinone in patients with AIDS-related&#xD;
      Kaposi's sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty-eight patients (14 per cohort) receive daily vesnarinone at one of two doses. At least&#xD;
      seven patients at the lower dose must have completed 2 weeks of therapy before subsequent&#xD;
      patients are entered at the higher dose. Patients who successfully complete 16 weeks of&#xD;
      treatment may receive maintenance therapy for the duration of the study (approximately 12-18&#xD;
      months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>28</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vesnarinone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.&#xD;
&#xD;
          -  Acyclovir as acute treatment for herpes outbreaks.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Limited electron-beam radiation therapy to non-marker lesions for treatment of&#xD;
             Kaposi's sarcoma.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  Kaposi's sarcoma.&#xD;
&#xD;
          -  No current constitutional signs of HIV disease or AIDS-defining conditions other than&#xD;
             Kaposi's sarcoma.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Active malignancy other than Kaposi's sarcoma, cutaneous basal cell carcinoma, or in&#xD;
             situ carcinoma of the cervix.&#xD;
&#xD;
          -  Current significant cardiac disease or anomaly (including prolonged QTC on EKG).&#xD;
&#xD;
          -  Abnormal cardio-thoracic ratio on chest x-ray.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents, including ddI, ddC, AZT, and d4T.&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Investigational HIV drugs/therapies including vaccines (except those on treatment IND&#xD;
             for approved indications).&#xD;
&#xD;
          -  Other anti-Kaposi's sarcoma/HIV drugs.&#xD;
&#xD;
          -  Corticosteroids (other than topical).&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Megestrol acetate.&#xD;
&#xD;
          -  Agents known to cause neutropenia.&#xD;
&#xD;
          -  Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg&#xD;
             sulfamethoxazole thrice weekly.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy including electron beam irradiation (other than limited&#xD;
             electron-beam radiation to non-marker lesions for treatment of Kaposi's sarcoma).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Prior history of significant cardiac disease or anomaly.&#xD;
&#xD;
          -  History of agranulocytosis or severe grade 3 drug-induced neutropenia or documented&#xD;
             abnormalities in granulocyte function.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  AZT within 14 days prior to study entry.&#xD;
&#xD;
          -  Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Cytotoxic chemotherapy.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days prior to study entry:&#xD;
&#xD;
          -  Blood or cellular blood product. Active illicit drug abuse (specifically cocaine, amyl&#xD;
             nitrate, heroin, or other cardioactive agents).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900121973</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Petit RG, Miles S, Magpantay L, Mitsuyasu R. Vesnarinone inhibits AIDS-KS cells in culture. Int Conf AIDS. 1994 Aug 7-12;10(1):169 (abstract no PB0104)</citation>
  </reference>
  <verification_date>April 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>vesnarinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vesnarinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

